Type 2 Diabetes Drug Metformin, Sold Under Brand Names Such As Glucophage, Subject of Class Action Lawsuit – Drug Alleged To Contain “Dangerously High Levels of N-nitrosodimethylamine”
Kehoe Law Firm, P.C. is making consumers aware that on April 7, 2020, a class action lawsuit was filed against Amneal Pharmaceuticals LLC (“Amneal”) in United States District Court, District of New Jersey, regarding Defendant Amneal’s alleged “manufacturing, distribution, and sale of the generic medication metformin that contains dangerously high levels of N-nitrosodimethylamine (‘NDMA’), a carcinogenic and liver-damaging impurity.”
According to the class action complaint:
Metformin is a prescription medication that has been sold under brand names such as Glucophage. Metformin is used to control high blood sugar in patients with type 2 diabetes. However, Amneal’s manufacturing process has caused metformin to contain dangerously high levels of NDMA.
. . .
On March 2, 2020, Valisure, an online pharmacy registered with the U.S. Drug Enforcement Agency and Food & Drug Administration, ‘detected high levels of NNitrodimethylamine (‘NDMA’) in specific batches of prescription drug products containing metformin.' This included metformin manufactured by Amneal.
Amneal had not yet issued a recall of metformin and continues to tout on its website that it is ‘committed to quality and safety.’ However, these representations are false, as Defendant’s metformin medication [allegedly] contains the carcinogenic impurity NDMA. [Emphasis added.]